reports
Addex Amends its at the Market Offering Agreement With H.C. Wainwright...
Addex Amends its at the Market Offering Agreement With H.C. Wainwright & Co. Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 11, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it has amended its At The Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC (“H.C. Wainwright & Co.”) initially entered into on January 30, 2024. The at-the-market offering program enables A...
Addex Therapeutics Reports 2025 Third Quarter Financial Results and Pr...
Addex Therapeutics Reports 2025 Third Quarter Financial Results and Provides Corporate Update Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 4, 2025 - (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its financial results for the three-month and nine-month periods ended September 30, 2025, and provided a corporate update. “We continue to make great progress with our GABAB positive allosteric modulator (PAM) candidate in chr...
Addex Therapeutics to Report 2025 Third Quarter Financial Results And...
Addex Therapeutics to Report 2025 Third Quarter Financial Results And Host Conference Call on December 4, 2025 Geneva, Switzerland, December 1, 2025 - (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will report its Third Quarter 2025 Financial Results on December 4, 2025. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review of the Addex product pipeline during a teleconference and we...
Addex Increases Issued Share Capital to Create Treasury Shares
Addex Increases Issued Share Capital to Create Treasury Shares Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 29, 2025 - (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that 34,300,000 new registered shares at a nominal value of CHF 0.01 have been issued and fully subscribed by Addex Pharma S.A, its 100% wholly-owned subsidiary. The new shares, issued from the Company’s capital band, are listed on the SIX Swiss Excha...
Addex Therapeutics Reports 2025 Half Year and Second Quarter Financial...
Addex Therapeutics Reports 2025 Half Year and Second Quarter Financial Results and Provides Corporate Update Cash position of CHF 2.3 million at end of H1 2025GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in disease models Regained rights to phase 2 mGlu2 PAM asset, ADX71149Indivior advanced GABAB PAM substance use disorders program successfully through IND enabling studiesEntered option agreement with Sinntaxis for exclusive license to intellectual property covering the use of mGlu5 NAM in brain injury recoveryInvested in Stalicla SA, confirming commitment to ...
Addex Therapeutics to Report 2025 Half-year and Second Quarter Financi...
Addex Therapeutics to Report 2025 Half-year and Second Quarter Financial Results on September 30, 2025 and Host Conference Call on October 1, 2025 Geneva, Switzerland, September 26, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will report its Half-Year and Second Quarter 2025 Financial Results on September 30, 2025 and host a conference call to discuss the results on October 1, 2025. Tim Dyer, CEO and Mikhail Kalinich...
Addex Appoints Bank of New York Mellon as Depositary Bank
Addex Appoints Bank of New York Mellon as Depositary Bank Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 23, 2025 - (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced the appointment the Bank of New-York Mellon (BNY) as its new ADS depositary agent. This change is expected to become effective on October 6, 2025. The appointment of BNY has no impact on the fees paid by ADS holders. At the effective date, no action will be...
Addex Leads CHF 2 Million Investment in Stalicla to Advance Precision ...
Addex Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine in Neuropsychiatric Disorders Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland – June 30, 2025 – (SIX: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced it has led a CHF 2 million investment in Stalicla, a clinical-stage company focused on precision medicine for neurodevelopmental and neuropsychiatric disorders. Stalicla will use the financing to advance its portfolio of auti...
Addex Shareholders Approve All Resolutions at Annual General Meeting
Addex Shareholders Approve All Resolutions at Annual General Meeting Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 25, 2025 - (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that its shareholders approved, with a large majority, all proposals of the board of directors in its 2025 Annual General Meeting (AGM). The votes represented 30.18% of the company's outstanding capital. Addex shareholders approved the 2024 annual report, the 2024 annual financial state...
Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corp...
Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Update Strong cash position of CHF2.8 million at end of Q1 2025GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in disease models Regained rights to our phase 2 mGlu2 PAM asset, ADX71149Indivior advanced GABAB PAM Substance use disorders program successfully through IND enabling studiesEntered option agreement with Sinntaxis for an exclusive license to intellectual property covering the use of mGlu5 NAM in brain injury recovery Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerla...
Addex Therapeutics to Release Q1 2025 Financial Results and Host Confe...
Addex Therapeutics to Release Q1 2025 Financial Results and Host Conference Call on June 19, 2025 Geneva, Switzerland, June 18, 2025 - (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will issue its Q1 2025 Financial Results on June 19, 2025. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review of the Addex product pipeline during a teleconference and webcast for investors, analysts and me...
Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in...
Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Multiple Chronic Cough Preclinical Models Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 6, 2025 - (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today robust anti-tussive activity of its novel gamma-aminobutyric acid sub-type B receptor (GABAB) positive allosteric modulator (PAM) in multiple preclinical models of chronic cough compared to reference drugs...
Addex to Present Positive GABAB PAM Chronic Cough Data at the 10th Ame...
Addex to Present Positive GABAB PAM Chronic Cough Data at the 10th American Cough Conference Geneva, Switzerland, June 5, 2025 - (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that preclinical data from its gamma-aminobutyric acid sub-type B receptor (GABAB) positive allosteric modulator (PAM) cough program will be presented at the 10th American Cough Conference (June 6-7) in Dulles, VA. A presentation given by Mikhail Kalinichev, Head of Translatio...
Addex Convenes Annual General Meeting 2025
Addex Convenes Annual General Meeting 2025 Geneva, Switzerland, June 3, 2025 - (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that its 2025 Annual General Meeting will take place on Tuesday June 24, 2025, at 11:00 am CEST at the Campus Biotech, Chemin des Mines 9, 1202 Geneva (doors open at 10:30 am). Agenda 1. Approval of the Annual Report, the Annual Financial Statements and the Consolidated Financial Statements for the business year 20...
Addex Partner Indivior Advances GABAB Positive Allosteric Modulator Pr...
Addex Partner Indivior Advances GABAB Positive Allosteric Modulator Program Successfully Through IND Enabling Studies Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 12, 2025 - (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today partner Indivior has successfully advanced its GABAB positive allosteric modulator (PAM) program through IND enabling studies. This is the final preclinical development stage before clinical studies can be start...
Addex Enters Option Agreement with Sinntaxis for an Exclusive License ...
Addex Enters Option Agreement with Sinntaxis for an Exclusive License to Intellectual Property Covering the Use of mGlu5 Inhibitors in Brain Injury Recovery Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 30, 2025 - (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that it has entered into an option- and collaboration agreement with Sinntaxis AB () for an exclusive license to intellectual property covering the use of metabotropic gl...
Addex Reports Full Year 2024 Financial Results and Provides Corporate ...
Addex Reports Full Year 2024 Financial Results and Provides Corporate Update Launched Neurosterix with Perceptive Advisors, raising USD 65 million in Series A to advance preclinical portfolioIndivior selected GABAB PAM drug candidate and started IND enabling studies for development in substance use disordersAddex selected independent GABAB PAM drug candidate for development in chronic coughRepositioned our phase 2 mGlu5 NAM asset, dipraglurant in brain injury recoveryRegained rights to our phase 2 mGlu2 PAM asset, ADX71149 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, Ap...
Addex Therapeutics to Release Full-Year 2024 Financial Results and Hos...
Addex Therapeutics to Release Full-Year 2024 Financial Results and Host Conference Call on April 25, 2025 Geneva, Switzerland, April 24, 2025 - (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will issue its Full-Year 2024 Financial Results on April 25, 2025. Tim Dyer, CEO, and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review of the Addex product pipeline during a teleconference and webcast for investor...
Addex Regains Rights to Phase 2 mGlu2 PAM Asset ADX71149
Addex Regains Rights to Phase 2 mGlu2 PAM Asset ADX71149 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 17, 2025 - (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that following the previously announced termination of development of ADX71149 (JNJ-40411813) in epilepsy, its partner Janssen Pharmaceuticals, Inc. (now known as J&J Innovative Medicine) has return all development and commercialization rights to ADX71149 (JNJ-40411813)...
Addex to Present at the 2025 Swiss Equities Baader Conference
Addex to Present at the 2025 Swiss Equities Baader Conference Geneva, Switzerland, January 8, 2025 - (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that Dr Robert Lütjens, Head of Discovery - Biology, will present at the being held in Bad Ragaz, Switzerland, January 08-10, 2025. In his presentation, Dr Lütjens will provide a corporate update and discuss recent advances from Addex’s CNS pipeline. Presentation Details:Date: Friday, January 10, 2025Tim...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.